Levofree (Levodropropizine)

Levodropropizine acts on sensory nerve endings in the respiratory tract, blocking the activation of cough receptors. By inhibiting the peripheral afferent signals that trigger the cough reflex, it lowers the frequency and intensity of coughing without affecting central brain pathways.

The appropriate dose of Levofree is determined by the prescribing healthcare professional based on the patient’s age, weight, renal function and severity of cough. Exact dosing regimens are not disclosed here and should follow the prescriber’s instructions.

Safety data for levodropropizine in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Levofree.

To order Levofree, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Levofree’s active ingredient, levodropropizine, is a peripheral antitussive, unlike central agents such as codeine that act on the brainstem. This peripheral action reduces the risk of sedation, dependence and respiratory depression, making Levofree a preferable option for patients who need cough relief without central side effects.

Levofree should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme temperatures to maintain its stability and efficacy throughout its shelf life.

Levofree is taken orally. The tablet or liquid (depending on the marketed form) should be swallowed with a glass of water, following the dosage instructions provided by the prescriber. It can be taken with or without food, unless otherwise advised.

Serious adverse reactions, although rare, include allergic responses such as rash, urticaria, angioedema, severe skin conditions like Stevens‑Johnson syndrome, hepatic enzyme elevations and hematologic abnormalities such as neutropenia. Patients should seek immediate medical attention if they experience any of these symptoms.

Levofree should be avoided in individuals with known hypersensitivity to levodropropizine or any excipients in the formulation. Patients with severe hepatic impairment or those taking contraindicated medications (e.g., strong CYP3A4 inhibitors) should not use the product without medical supervision.